Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

2009; Springer Nature; Volume: 100; Issue: 2 Linguagem: Inglês

10.1038/sj.bjc.6604838

ISSN

1532-1827

Autores

John P. Neoptolemos, Deborah Stocken, Catrin Tudur Smith, Claudio Bassi, Paula Ghaneh, E Owen, Malcolm J. Moore, Robert Padbury, Ryuichiro Doi, David B. Smith, Markus W. Büchler,

Tópico(s)

Renal cell carcinoma treatment

Resumo

The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI=0.55–0.88) P=0.003, and the median survival of 23.2 (95% CI=20.1–26.5) months with 5FU/FA vs 16.8 (95% CI=14.3–19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.

Referência(s)